Navigation Links
Oncolytics Biotech(R) Inc. Announces Positive Results of U.K. Phase II REOLYSIN(R) and Radiation Combination Clinical Trial
Date:4/7/2009

rimary endpoint was objective tumour response rate in treated lesions. Secondary endpoints were to evaluate viral replication, immune response, and safety. Eligible patients included those diagnosed with advanced or metastatic cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists. The Phase II trial followed a successful Phase Ia/Ib combination REOLYSIN/radiation trial in which local and systemic responses were noted.

The Principal Investigator for the trial is Dr. Kevin Harrington of the Targeted Therapy Laboratory, Cancer Research UK Centre for Cell and Molecular Biology at The Institute of Cancer Research and Honorary Consultant in Clinical Oncology at The Royal Marsden NHS Foundation Trust.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combination REOLYSIN/radiation clinical trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and developme
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Drug Discovery Technologies - A Global U... http://www.reportlinker.com/p0164246/Drug-Discove...--Opportunities.html ,, Drug discovery has bec...aceutical company,s business strategy. There are a...
(Date:12/2/2009)...wswire-FirstCall/ - Oncolytics Biotech Inc. ("Onco... announced today that in connection with its previ...ve exercised in full their over-allotment option a...t is comprised of one common share and 0.4 of a co...ce of US$3.00 per unit. Each whole common share pu...
(Date:12/2/2009)..., December 2 Gamida Cell announced...cal (animal study) safety and,efficacy of a gene t...l,Cornell Medical College and Gamida Cell. The pro... such as Cooley,s Anemia. , Gamida Cell i...x vivo,populations of stem/progenitor cells. The ...
(Date:12/2/2009)...ire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: A...aceutical company focused on endocrine therapy and...Drug Administration (FDA) has granted Fast Track d...bitor compound, perifosine (KRX-0401), for the tre...ryx Biopharmaceuticals, Inc. ("Keryx") ( KERX), is...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3
...Inc. on Thursday reported significant revenue inc...sales for its Mediasite communications systems, an...s. , ,In reporting its third quarter and nine-mont...arter revenues were 83 percent higher than those o...ion to $2.2 million. , ,For the nine-month period,...
...lent partners" of every online business. A good pa...ur business. A bad one costs you time, money, and ...online is finding the right web host - the company... and internet connectivity you need to share a sit...n ,From a customer,s perspective, the geographic ...
... on every desktop - the future of learning is a co... that can engage diverse audiences - from uncommun...ed Forces - in methods that can blend reality with...obile future was one of the topics discussed at th...ce here. Researchers presented how the personal di...
Other Biology Technology:Sonic Foundry reports 12th consecutive quarter of record sales for Mediasite 2Silent partners: Selecting a web hosting company 2Silent partners: Selecting a web hosting company 3Silent partners: Selecting a web hosting company 4PDAs add new dimension to distance learning 2PDAs add new dimension to distance learning 3
(Date:12/2/2009)...exposed to secondhand cigarette smoke have an incr... even if they never smoked. , Results of this s...kers & Prevention , a journal of the American Asso...tobacco focus in the December issue. , This yea...osed with lung cancer; more than 159,000 will die ...
(Date:12/2/2009)...merican adolescents exposed to cigarette smoking s...it themselves, and this may be part of the accultu... according to new study findings. , "Our study s...es and highlights the global implementation of the... Tobacco Control, which includes guidelines for co...
(Date:12/2/2009)...iversity of Georgia College of Veterinary Medicine...ld open new avenues for treating Ichthyophthirius ... protozoan parasite that commonly attacks freshwat...ng, researchers found that Ich harbors two apparen..., which are usually found free-living, and Rickett...
Breaking Biology News(10 mins):Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 2UGA researchers lead team in discovery involving devastating freshwater fish parasite, 'Ich' 3Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 1Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 2Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 3Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 4Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 5Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 6Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 7Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 8Four Studies Published in The Lancet Show roflumilast 28Daxas 28R 29 29 a New Oral Approach to COPD Improves Lung Function and Reduces Exacerbation 4911 9MPA Media Launches New Chiropractic Publication Dynamic Chiropractic PracticeINSIGHTS 55577 1MPA Media Launches New Chiropractic Publication Dynamic Chiropractic PracticeINSIGHTS 55577 2Champions Biotechnology Reports Fiscal 2009 Full Year Financial Results 13727 1Champions Biotechnology Reports Fiscal 2009 Full Year Financial Results 13727 2Champions Biotechnology Reports Fiscal 2009 Full Year Financial Results 13727 3Champions Biotechnology Reports Fiscal 2009 Full Year Financial Results 13727 4Champions Biotechnology Reports Fiscal 2009 Full Year Financial Results 13727 5
...lar cleanup-mechanism known as autophagy can accel...leads to neural degeneration. In an upcoming issue...r Biological Studies report for the first time tha... in the nervous system of fruit flies prevented th... neurons and promoted longevity. , We discovered ...
...e first time, scientists at Weill Cornell Medical ...e a cellular mechanism that,s crucial to how brain...aid to rest a competing theory as to how key cellu... -- work. , The scientists published their findi...f the National Academy of Sciences (Dec. 18 print ...
... environmental scientist will head a new internati... slimy, snake-like fish considered worldwide to be...n in Lake Ontario. , Biology professor Peter Hods... received $536,450 from the Natural Sciences and E...ystery of Lake Ontarios disappearing eel populatio...
Other Biology News:Aging gracefully requires taking out the trash 2Aging gracefully requires taking out the trash 3Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 2Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling 3Where have all the lake eels gone? Queen's prof asks 2
...bilizing 400g of purified RNA samples., , This...of aqueous RNA samples that have been pre-purified...ol/chloroform, silica, oligo dT etc or other kits....mponents for the stabilization of nanogram to mill...
Pyrex brand Fernback baffled culture flask from Sigma-Aldrich
...-FRT template is designed to allow neomycin/kanam.... The FRT-PGK-gb2-neo-FRT template encodes the ne...prokaryotic promoter (gb2) for expression of kanam...oter (PGK) for expression of neomycin resistance i...
...diameter, 7 inch long PYREX NMR tubes are made fro...h ground joints, valves, and vacuum racks. They ar...om 300 to 500MHz. They have an O.D. of 4.97 + 0.00...se NMR tubes can be used with the PYREX Microcell ...
Biology Products: